Age and CMV are not associated with clinical or immunological response to immune checkpoint blockade
Edwards, J. M.; Senthi, S.; Smith, R.; Burridge, H.; Owens, C.; Shackleton, M.; Andrews, M. C.; van Zelm, M. C.
Show abstract
Ageing and cytomegalovirus (CMV) infection drive major alterations to T-cell immunity. Age is also associated with an increased risk of cancers including melanoma, which is treated with T-cell modifying immune checkpoint blockade (ICB). However, the extent to which age, CMV, and treatment-induced immune changes interact to shape clinical outcomes remains poorly understood. We investigated this through flow cytometric evaluation of pre- and early on-treatment blood samples of 79 advanced melanoma patients. Age and CMV infection were associated with significant and largely distinct changes to T cell phenotype pre-treatment but had no impact on clinical outcome. Older patients ([≥]65 years) had fewer CD8+ Tnaive, CD4+ Tcm, TFH, and B cells, and increased CD8+ TemRA, but similar cytokine and inhibitory marker expression. Conversely, CMV drove expansion of CD8+ and CD4+ TemRA cells with enhanced effector function without reducing naive populations. One cycle of PD-1 and CTLA-4 ICB induced immune cell expansion and phenotype changes of greater magnitude and partially distinct from those seen during PD-1 with or without LAG-3 ICB, but these effects were largely independent of age or CMV serostatus. Hence, neither ageing nor CMV were associated with clinical outcome or immunological response to ICB in advanced melanoma patients.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- The Healthy Human Global Project - Hong Kong : a community-based cross-sectional study of a healthy Asian population 89%
- Spatial transcriptomics analysis identifies a unique tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease 89%
- COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection 89%
Similar papers in this journal
- Epigenetic biomarkers of ageing are predictive of mortality risk in a longitudinal clinical cohort of individuals diagnosed with oropharyngeal cancer. 91%
- Epigenetic Age Acceleration in Surviving versus Deceased COVID-19 Patients with Acute Respiratory Distress Syndrome following Hospitalization 90%
- Epigenetic clocks predict prevalence and incidence of leading causes of death and disease burden 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.